Discovery of LX2761,
a Sodium-Dependent Glucose Cotransporter
1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment
of Diabetes
Version 2 2017-01-20, 18:24
Version 1 2017-01-13, 22:13
Posted on 2017-01-20 - 18:24
The increasing number of people afflicted
with diabetes throughout
the world is a major health issue. Inhibitors of the sodium-dependent
glucose cotransporters (SGLT) have appeared as viable therapeutics
to control blood glucose levels in diabetic patents. Herein we report
the discovery of LX2761, a locally acting SGLT1 inhibitor that is
highly potent in vitro and delays intestinal glucose absorption in
vivo to improve glycemic control.
CITE THIS COLLECTION
DataCite
No result found
Goodwin, Nicole C.; Ding, Zhi-Ming; Harrison, Bryce A.; Strobel, Eric D.; Harris, Angela L.; Smith, Melinda; et al. (2017). Discovery of LX2761,
a Sodium-Dependent Glucose Cotransporter
1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment
of Diabetes. ACS Publications. Collection. https://doi.org/10.1021/acs.jmedchem.6b01541
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
AUTHORS (19)
- NGNicole C. GoodwinZDZhi-Ming DingBHBryce A. HarrisonESEric D. StrobelAHAngela L. HarrisMSMelinda SmithATAndrea Y. ThompsonWXWendy XiongFMFaika MseehDBDebra J. BruceDDDamaris DiazSGSuma GopinathanLLLing LiEOEmily O’NeillMTMary ThielAGAlan G. E. WilsonKCKenneth G. CarsonDPDavid R. PowellDRDavid B. Rawlins
